Litigation Details for Lu v. Relypsa, Inc. (N.D. Cal. 2016)

« Back to Dashboard

Lu v. Relypsa, Inc. (N.D. Cal. 2016)

Docket		Date Filed	2016-08-12
Court	District Court, N.D. California	Date Terminated	2016-09-12
Cause	28:1331 Fed. Question: Securities Violation	Assigned To	William Horsley Orrick III
Jury Demand	Plaintiff	Referred To
Parties	HELEN TORLEY; JOHN A. ORWIN
Patents	7,556,799; 8,147,873; 8,216,560; 8,282,913; 8,287,847; 8,337,824; 8,475,780; 8,778,324; 8,889,115
Attorneys	Barbara Ann Rohr; Hilary Hellmuth Mattis
Firms	Faruqi & Faruqi LLP; Law Offices or Robert B. Mobasseri, P.C.
Link to Docket	External link to docket

Details for Lu v. Relypsa, Inc. (N.D. Cal. 2016)

Date Filed	Document No.	Description	Snippet	Link To Document
2016-08-12				External link to document
2016-08-12	1		The issued methods of treatment patents (U.S. Patent Nos. 7,556,799, 24 8,216,560, 8,287,847, 8,475,…successfully obtained 9 patents 20 associated with Veltassa. The patents and patent applications relating…Relypsa. The issued composition of matter patents (U.S. Patent Nos. 8,147,873, 8,282,913, 22 and 8,337,824…evergreening its patent portfolio. Relypsa 2 currently has at least two pending patent applications…of its patent portfolio. Indeed, Relypsa appears to be in the process of evergreening its patent 19 portfolio	External link to document

Lu v. Relypsa, Inc. Litigation Summary and Analysis, Case No. 3:16-cv-04605

Last updated: August 3, 2026

Lu v. Relypsa, Inc., No. 3:16-cv-04605, was a federal shareholder lawsuit challenging Relypsa's proposed acquisition by Vifor Pharma. The case was a merger-related securities and disclosure action, not a patent-infringement dispute involving Veltassa or Relypsa's potassium-binding technology. The transaction closed in 2016, and the litigation did not produce a reported merits ruling invalidating the merger or imposing patent-related restrictions on Vifor's commercial rights. [1]-[3]

What was Lu v. Relypsa, Inc. about?

The plaintiff challenged disclosures made to Relypsa shareholders in connection with Vifor's $32-per-share cash acquisition of Relypsa. The complaint alleged that the proxy statement omitted or inadequately described material information concerning the merger process, Relypsa's financial projections, and the financial adviser analyses supporting the transaction.

The action was brought in the U.S. District Court for the Northern District of California under docket number 3:16-cv-04605. Relypsa was headquartered in Redwood City, California, which explains the federal venue. [1]

The case concerned the adequacy of shareholder disclosures under the federal securities laws, principally Section 14(a) of the Securities Exchange Act of 1934 and Rule 14a-9. The plaintiff also pursued related claims against directors and control persons under Section 20(a). The litigation did not challenge the FDA approval of Veltassa, the validity of Relypsa patents, or the company's right to market patiromer.

When was the Relypsa-Vifor transaction announced and completed?

Vifor announced the acquisition of Relypsa in July 2016. The agreed consideration was $32 in cash for each Relypsa share, representing an equity value of approximately $1.5 billion. The transaction provided Vifor with control of Veltassa, Relypsa's patiromer product for hyperkalemia. [2]

The transaction timeline was as follows:

Event	Date or status
Vifor announces agreement to acquire Relypsa	July 2016
Federal shareholder litigation filed	2016
Relypsa shareholder approval process	2016
Transaction closes	September 2016
Vifor obtains Relypsa and Veltassa operations	September 2016
Case disposition	No reported merits judgment overturning the transaction

Relypsa's proxy statement described the transaction, board process, financial projections, adviser analyses, potential conflicts, and other shareholder-vote information. The plaintiff claimed that the disclosure package did not provide enough detail for shareholders to evaluate the deal. [3]

What claims did the plaintiff assert?

The lawsuit was structured as a disclosure-based merger challenge. The principal theories were:

1. Relypsa's proxy statement allegedly omitted material information.
2. The omissions allegedly rendered the proxy statement false or misleading under Section 14(a) and Rule 14a-9.
3. The individual directors were alleged to be liable as controlling or responsible persons under Section 20(a).
4. The plaintiff sought to delay or enjoin the shareholder vote and transaction, or obtain monetary relief and litigation fees.

Typical allegations in this category of case concern the presentation of:

• Relypsa's standalone financial forecasts;
• revenue, expense, and cash-flow assumptions;
• discounted cash-flow analyses;
• comparable-company analyses;
• precedent-transaction analyses;
• valuation ranges used by the investment bank;
• the board's consideration of alternatives;
• banker compensation and possible conflicts;
• the process leading to the Vifor transaction.

The legal issue was whether the allegedly omitted information would have been material to a reasonable shareholder. Courts generally distinguish between material information and requests for every underlying detail, draft, sensitivity analysis, or negotiating communication.

Was Lu v. Relypsa a patent case?

No. The case should not be classified as a patent litigation matter.

Issue	Status in Lu v. Relypsa
Patent infringement	Not the subject of the case
Patent validity	Not adjudicated
Patent inventorship	Not adjudicated
FDA approval of Veltassa	Not challenged
ANDA or Paragraph IV litigation	Not the subject of the case
Merger disclosure	Central issue
Shareholder vote	Central transaction event
Vifor acquisition of Relypsa	Underlying transaction

Relypsa's commercial asset was Veltassa, an oral patiromer product approved by the FDA in 2015 for the treatment of hyperkalemia. The acquisition transferred Relypsa's business and product rights to Vifor, but Lu did not determine the scope, enforceability, or expiration of any Veltassa-related patent. [2]-[4]

What was the litigation status and outcome?

The litigation did not result in a reported decision holding that the merger violated federal securities law. The transaction proceeded and closed in 2016. Public docket materials identify the action as a merger-related shareholder case, but the case did not generate a precedential opinion establishing a new rule for pharmaceutical mergers or disclosure standards. [1]

The practical outcome was therefore transaction completion rather than deal invalidation. As in many public-company merger disclosure cases, the principal litigation leverage existed before the shareholder vote. Once the deal closed, injunctive relief became unavailable or commercially ineffective, and the case's value shifted toward dismissal, settlement, supplemental disclosure issues, or a fee application.

The available record does not support treating the case as a successful challenge to Vifor's acquisition. It also does not support treating the case as a finding of fraud, director misconduct, or damages against Relypsa.

Did the case produce a settlement agreement?

The case did not produce a reported merits ruling that rescinded the transaction or awarded shareholder damages. Any disposition should be read primarily as a procedural resolution of a merger challenge after the transaction closed.

A merger-related disclosure case can resolve through:

• supplemental proxy disclosures before the vote;
• an agreement not to oppose the transaction;
• dismissal after closing;
• a release of claims;
• payment of plaintiff's attorneys' fees;
• or a combination of these measures.

The docket classification and transaction history indicate that Lu did not become a substantive post-closing damages action against Vifor's Veltassa business. No publicly reported settlement in the case created continuing restrictions on Vifor's ownership, marketing, manufacturing, or licensing of patiromer.

What did the case mean for Veltassa and Relypsa's patent estate?

The case had no direct effect on Veltassa's regulatory exclusivity or patent protection.

Relypsa's principal product was Veltassa, whose active pharmaceutical ingredient is patiromer. FDA approval, Orange Book listings, patent expiration dates, generic entry rights, and Paragraph IV litigation are separate regulatory and patent questions. They were not resolved in Lu v. Relypsa. [4]

Orange Book and FDA status

Veltassa was FDA-approved before the acquisition. The transaction did not constitute a new drug approval, a supplemental approval, or a transfer of FDA exclusivity rights. Vifor acquired the commercial business and assumed responsibility for the product through the transaction structure and subsequent corporate operations.

The case did not determine:

• whether a Veltassa patent was properly listed in the Orange Book;
• whether an ANDA applicant could certify under Paragraph IV;
• whether a generic patiromer product infringed;
• whether a formulation or method-of-use patent was valid;
• or whether FDA regulatory exclusivity blocked generic approval.

Formulation and method-of-use patents

Patiromer products may be protected through several types of intellectual property, including:

• composition claims;
• polymer or ion-exchange-resin claims;
• formulation claims;
• powder or suspension dosage-form claims;
• manufacturing-process claims;
• dosing and administration claims;
• treatment claims for hyperkalemia.

Lu did not construe or invalidate any such claims. No claim construction order, infringement judgment, or patent settlement from this case should be used to assess Veltassa's patent strength.

Did Lu create generic-entry risk for Veltassa?

No direct generic-entry risk arose from the case.

Generic risk for Veltassa would depend on the FDA's ANDA pathway, applicable Orange Book patents, Paragraph IV certifications, patent litigation, regulatory exclusivity, and the ability of an ANDA applicant to obtain approval after resolving listed patent barriers. Those issues were outside the scope of Lu.

The acquisition did, however, change the commercial owner of Veltassa. Vifor obtained the product while Relypsa remained a relatively concentrated commercial asset. That ownership change was commercially significant, but the lawsuit did not reduce or expand Vifor's statutory or patent rights.

Which companies were challenging Relypsa in Lu?

The plaintiff was a Relypsa shareholder, identified in the case caption as Lu. The defendants included Relypsa and persons associated with the company and transaction. The case was not an ANDA action brought by a generic manufacturer.

No generic drug company was the principal adversary in this case. The litigation therefore differs from pharmaceutical patent cases in which a branded company sues an ANDA applicant under the Hatch-Waxman Act.

The relevant transaction parties were:

Party	Role
Lu	Shareholder plaintiff
Relypsa, Inc.	Target company and principal corporate defendant
Relypsa directors or officers	Individual defendants associated with the transaction
Vifor Pharma	Acquirer and transaction counterparty
Generic manufacturers	Not the principal litigants in this action

How strong was the litigation position?

The plaintiff's leverage was strongest before the shareholder vote, when a disclosure ruling could delay the transaction or require additional disclosures. After closing, the economic and procedural value of injunctive relief declined sharply.

The case did not establish that:

• the $32-per-share price was inadequate;
• the board breached fiduciary duties;
• the Vifor transaction was unfair;
• Relypsa's financial adviser acted improperly;
• Vifor made misleading disclosures;
• or shareholders suffered compensable damages.

The absence of a reported merits decision limits the case's value as precedent. For transaction-risk analysis, the case is best treated as an example of disclosure and merger-process litigation rather than as evidence of a defect in Vifor's acquisition or Relypsa's pharmaceutical intellectual property.

What is the commercial significance of the case?

The commercial effect was limited but relevant to transaction execution.

Relypsa's value was closely linked to Veltassa's future sales, reimbursement, physician adoption, manufacturing scale-up, and competitive position in hyperkalemia. A shareholder challenge could have delayed the acquisition, increased transaction costs, required supplemental disclosures, or altered the timetable for control transfer.

The case did not produce a public-company breakup, acquisition price revision, or loss of Veltassa rights. Vifor completed the transaction and continued the commercial development of patiromer through its broader pharmaceutical platform.

From a diligence perspective, Lu should be reviewed for:

• the completeness of the Relypsa proxy disclosure;
• board and adviser process allegations;
• any fee award or dismissal order;
• representations and litigation schedules associated with the merger;
• and distinctions between transaction litigation and separate patent or regulatory matters.

How does Lu compare with Relypsa patent litigation?

Category	Lu v. Relypsa	Relypsa patent litigation
Legal basis	Securities disclosure and merger law	Patent law and Hatch-Waxman law
Plaintiff	Shareholder	Usually branded company or patent owner
Defendant	Target company, directors, transaction parties	ANDA applicant or competing drug company
Product issue	Value of Relypsa and Veltassa in the merger	Scope and validity of drug-related patents
FDA issue	None directly	ANDA approval and patent certification
Remedy sought	Injunction, disclosure, damages, fees	Injunction against generic launch, damages, declaration
Effect on Veltassa patents	None established	Potentially direct
Effect on acquisition	Possible delay or disclosure changes	Usually no effect on ownership

This distinction is material. A search for "Relypsa litigation" can combine shareholder, patent, regulatory, employment, and commercial disputes. Lu belongs in the shareholder-litigation category.

Key Takeaways

• Lu v. Relypsa, Inc., No. 3:16-cv-04605, was a merger-related shareholder disclosure case.
• The litigation challenged disclosures surrounding Vifor Pharma's $32-per-share acquisition of Relypsa.
• The transaction closed in 2016.
• The case was not a Veltassa patent-infringement or Hatch-Waxman Paragraph IV action.
• No reported merits ruling invalidated the acquisition or found Relypsa's directors liable for securities fraud.
• The case did not determine Veltassa's Orange Book status, patent expiration, formulation protection, method-of-use protection, or generic-entry timing.
• Vifor obtained Relypsa and its patiromer business despite the litigation.
• The case has limited precedential value for pharmaceutical patent, FDA, or generic-launch analysis.

FAQs

Did Lu v. Relypsa challenge Veltassa's FDA approval?

No. The case challenged merger-related shareholder disclosures and did not seek to revoke, delay, or modify FDA approval of Veltassa.

Did Lu v. Relypsa involve a Paragraph IV certification?

No. The case was not an ANDA patent action and did not involve a generic manufacturer's Paragraph IV certification.

Did the lawsuit stop Vifor from acquiring Relypsa?

No. Vifor completed the acquisition in 2016.

Did the court invalidate any Relypsa patent?

No reported ruling in Lu invalidated or construed a Relypsa patent.

Is Lu v. Relypsa evidence that Veltassa faced imminent generic competition?

No. The case does not establish generic-entry timing. That analysis requires separate review of FDA exclusivity, Orange Book listings, patent terms, ANDA filings, and Hatch-Waxman litigation.

References

1. U.S. District Court for the Northern District of California. (2016). Lu v. Relypsa, Inc., et al., No. 3:16-cv-04605, docket materials.

2. Vifor Pharma. (2016, July). Vifor Pharma to acquire Relypsa, Inc. for $32 per share in cash. Company transaction announcement.

3. Relypsa, Inc. (2016). Definitive proxy statement relating to the proposed merger with Vifor Pharma. U.S. Securities and Exchange Commission.

4. U.S. Food and Drug Administration. (2015). Veltassa (patiromer) prescribing information and approval materials. FDA.